11 results about "Metastasis Suppression" patented technology

A series of 1, 3, 5-triazine compounds that exhibit potent inhibition of endosomal trafficking and autophagy is provided. These compounds effectively suppress cancer cell proliferation, growth, and migration, induce cell cycle arrest at the G0 / G1 phase, promote cancer cell death via non-apoptotic pathways, and inhibit tumor sphere formation. Moreover, select compounds within this series demonstrate significant inhibition of tumor growth and metastasis in mouse models of lung cancer and melanoma. Additionally, they modulate macrophage polarization and the tumor microenvironment by regulating cytokine secretion. These findings highlight the potential of 1, 3, 5-triazine compounds as promising antitumor agents.

This invention belongs to the field of tumor immunotherapy and provides the application of Hdac3 gene knockout formulations or Ikkα gene knockout formulations in the preparation of drugs that inhibit tumor metastasis. The research results of this invention show that Hdac3 and Ikkα gene mutations significantly inhibit lung tumor metastasis and prolong the survival of mice, and this metastasis inhibition is independent of T, B, and NK cells. Simultaneously, this invention also discovers that Hdac3 and Ikkα mutations inhibit lung tumor metastasis by affecting the sensitivity of tumor cells to tumor necrosis factor, making tumor cells more susceptible to apoptosis, thereby providing a method for sustained in vivo killing of tumor cells. This invention also provides a mutant vector, which exhibits good anti-tumor metastasis effects.

Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part, thereby inhibiting the metastatic and invasive growth of malignant cells in a cancer patient.

The application discloses a preparation method and application of cell membrane-derived nanovesicles with specific targeting tumor and metastasis inhibition. The CD82 overexpression lung epithelial cell HBE cell strain is constructed through gene engineering, cell membranes are extracted in vitro, AS1411 aptamer is modified, and a chemotherapeutic drug, doxorubicin (DOX), is loaded to prepare an engineered nanovesicle drug delivery system. The engineered nanovesicle drug delivery system prepared by the application is proved to have multiple effects such as targeting triple-negative breast cancer, inhibiting metastasis and inducing triple-negative breast cancer cell apoptosis through in-vitro and in-vivo experiments. The application fills the gap of the extracellular vesicles as a drug carrier, and provides a new thought and scientific basis for the clinical treatment of triple-negative breast cancer.

The invention discloses an application of a miR-1246 inhibitor in preparation of a medicine for preventing or treating postoperative metastasis of hepatocellular carcinoma (HCC). According to the application disclosed by the invention, the expression of miR-1246 in the serum exosome of an HCC patient after operation is obviously up-regulated, the expression of BMP9 protein is inhibited by directly targeting a GDF2 gene, and a downstream SMAD7-mediated metastasis inhibition signal channel is blocked, so that the HCC cell metastasis is driven, that is, the metastasis promoting process can be effectively reversed by inhibiting the function of miR-1246. In-vivo and in-vitro experiments prove that by using the miR-1246 inhibitor, the HCC cell anoikis apoptosis resistance, migration, invasion and in-vivo lung metastasis induced by the serum exosome after operation can be remarkably inhibited. The miR-1246 inhibitor can also be combined with a recombinant protein BMP9 to generate a synergistic anti-metastasis effect. Therefore, the miR-1246 inhibitor provides a new target and strategy for developing a novel anti-HCC postoperative metastasis drug.

The present application relates to the structure of a clero dene diterpene compound in fierce taste foot bone crisp, preparation method and its application in antitumor, the compound has the structure as shown in figure 1.The compound of the present application has tumor proliferation and metastasis inhibitory activity and angiogenesis inhibitory activity, and can be used for the development and application of antitumor drugs.

A series of 1,3,5-triazine compounds that exhibit potent inhibition of endosomal trafficking and autophagy is provided. These compounds effectively suppress cancer cell proliferation, growth, and migration, induce cell cycle arrest at the G0 / G1 phase, promote cancer cell death via non-apoptotic pathways, and inhibit tumor sphere formation. Moreover, select compounds within this series demonstrate significant inhibition of tumor growth and metastasis in mouse models of lung cancer and melanoma. Additionally, they modulate macrophage polarization and the tumor microenvironment by regulating cytokine secretion. These findings highlight the potential of 1,3,5-triazine compounds as promising antitumor agents.

Provided are methods of increasing a response to a chemotherapeutic agent or an immunotherapeutic agent in a patient in need thereof, and methods of treating cancer in a patient in need thereof, comprising administering to the patient a chemotherapeutic agent or an immunotherapeutic agent and a metastasis inhibiting compound, as described in this disclosure.

The present invention relates to a composition for inhibiting the growth of cancer stem cells, and a use thereof. A WDR34 inhibitor of the present invention inhibits the conversion of cancer cells into cancer stem cells and exhibits activity of inhibiting self-renewal, invasion, and migration of cancer stem cells, and thus can be effectively used as a cancer cell growth or metastasis inhibitor or a cancer stem cell growth inhibitor.

The invention belongs to the field of antibody preparation, and particularly relates to an antibody specifically bound with GRP78 and application thereof. The present invention relates to an anti-GRP78 antibody comprising a heavy chain CDR and a light chain CDR of a specific sequence, or an antigen-binding fragment thereof. The anti-GRP78 antibody has very high specificity and affinity for GRP78, has a very significant growth-inhibiting effect, infiltration-inhibiting effect, and angiogenesis-inhibiting effect on colorectal cancer cell lines, and is expected to be effectively used as a composition for treating colorectal cancer, inhibiting metastasis, and inhibiting angiogenesis.

This invention discloses a 1,3-dithioheterocyclic fused naphthalenetetracarboxylic acid diimide derivative, a near-infrared II photothermal molecule containing it, its preparation method, and its applications, belonging to the field of biomedical technology. The thioheterocyclic fused naphthalenetetracarboxylic acid diimide derivative provided by this invention has a donor-acceptor-donor configuration. The thioheterocyclic fused naphthalenetetracarboxylic acid diimide derivative and doxorubicin are co-encapsulated in a temperature / pH dual-responsive nanogel matrix to form a PND core. Nasopharyngeal carcinoma tumor cell membranes expressing growth arrest-specific gene 6 are coated on the PND surface to construct a nanodecoy with homologous targeting capability. This integrates four major functions—homological targeted delivery, dual-mode imaging guidance, local chemotherapy-photothermal synergistic therapy, and systemic metastasis inhibition—into a single platform, simultaneously tackling the dual challenges of in situ treatment of nasopharyngeal carcinoma and prevention and control of lung cancer cell metastasis.